Additionally, small molecule inhibitors targeting B cell activation pathways, such as Bruton’s tyrosine kinase (BTK) inhibitors, are currently under investigation in clinical trials for various autoimmune conditions, offering another avenue for potential IDD treatment (87). The gene discussed is BTK; the disease is Autoimmunity.